Skip to main content
. 2020 Apr 25;8(2):120–126. doi: 10.14218/JCTH.2019.00012

Table 2. Changes of parameters after 6 months of physical training in the low intensity exercise group and moderate intensity exercise group.

Parameters Low intensity exercise group (n=19) Moderate intensity exercise group (n=18)
Before 6 months of physical training After 6 months of physical training p value Before 6 months of physical training After 6 months of physical training p value
BMI (kg/m2) 26.1±2.1 25.9±1.8 0.623 26.9±1.9 26.7±2.0 0.428
Waist hip ratio 1.01±0.35 0.93±0.22 < 0.001 0.97±0.04 0.96±0.04 0.262
Waist height ratio 0.59±0.04 0.57±0.4 < 0.001 0.56±0.04 0.55±0.04 0.168
SBP (mm Hg) 156.6±18.9 140.1±21.3 < 0.001 132.2±13.2 116.4±8.9 0.001
DBP (mm Hg) 90.7±10.1 85.8±11.1 0.018 87.4±8.3 77.8±8.6 0.005
FPG (mg/dL) 183.7±79.2 129.7±48.3 0.333 104±20.7 85.8±19.0 < 0.001
PGPG (mg/dL) 185.8±67.4 185.1±85.5 0.961 145.2±60.2 120.1±40.8 0.068
Triglycerides (mg/dL) 186.2±72.6 166.8±77.8 0.303 157.9±57.2 124.6±63.5 0.013
Cholesterol (mg/dL) 181.4±34.8 167.1±33.2 0.009 211.2±30.0 196.7±26.6 0.020
HDL (mg/dL) 42.1±8.9 37.8±6.7 0.001 46.0±4.8 41.5±6.8 0.006
LDL (mg/dL) 102.5±29.9 99.4±26.6 0.571 130.5±22.0 130.5±21.9 0.398
VLDL (mg/dL) 36.8±14.5 29.8±11.6 0.032 34.6±16.8 24.8±12.7 0.010
Bilirubin (mg/dL) 1.1±0.7 0.9±0.8 0.133 0.8±0.3 0.7 ±0.4 0.190
AST (U/L) 23.9±7.9 22.0±5.7 0.204 39.2±29.5 29.8±8.5 0.253
ALT (U/L) 26.3±13.1 22.6±6.6 0.205 61.8±30.2 29.1±9.8 0.002
ALP (U/L) 189.6±37.4 176.3±18.3 0.137 202.7±51.3 193.2±50.9 0.440
GGT (U/L) 52.7±49.6 36.7±25.7 0.033 61.3±51.3 37.4±24.1 0.024
HOMA-IR 3.75±5.27 2.71±2.60 0.466 2.56±2.55 1.69±2.59 0.005

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; PGPG, post-glucose load plasma glucose (after 2-h glucose load); HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; HOMA-IR, homeostatic model assessment of insulin resistance.